Contineum Therapeutics, Inc. (CTNM) Stock Forecast
CTNM analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 4.38 / 5 from 8 analysts
- Price target
- $22.14 average of analyst targets
- Upside to target
- +212.8% from the latest close
- Next earnings
- October 29, 2026 EPS estimate $-0.45
- 52-week range
- $7.08 – $17.57
CTNM analyst ratings
8 analystsNumber of analysts at each rating.
CTNM price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
CTNM earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.45 | −$0.51 | −$0.40 | −$0.45 | −0.6% | 7 |
| Current fiscal year (2026) | −$1.70 | −$1.85 | −$1.52 | −$2.17 | +21.9% | 7 |
| Next fiscal year (2027) | −$1.93 | −$2.55 | −$1.43 | −$1.70 | −13.7% | 7 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
CTNM revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 6 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 6 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 6 |
CTNM EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
CTNM EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.43 | −$0.46 | −$0.45 | −$0.45 | −$0.45 | +5.7% | 3 up · 3 down |
| Current fiscal year (2026) | −$1.65 | −$1.56 | −$1.56 | −$1.71 | −$1.70 | +3.0% | 1 up · 1 down |
| Next fiscal year (2027) | −$1.81 | −$1.82 | −$1.80 | −$1.92 | −$1.93 | +6.2% | 1 up · 2 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
CTNM earnings surprises
Reported EPS vs the consensus estimate for the last 11 quarters; CTNM beat in 5 of 11.
What analysts expect from CTNM
8 analysts cover Contineum Therapeutics; their consensus rating is buy (4.38 on a 1–5 scale, where 5 is a strong buy). The average price target is $22.14, 212.8% above the latest close of $7.08. Analysts expect earnings of −$1.70 per share for 2026, +21.9% from a year earlier. For 2027 the average estimate is −$1.93 per share. Contineum Therapeutics beat the EPS estimate in 5 of the last 11 quarters.
Related: CTNM income statement, CTNM key metrics, CTNM chart. See the CTNM stock overview for the latest quote and news.
CTNM forecast FAQ
What is Contineum Therapeutics's price target?
The average analyst price target for Contineum Therapeutics is $22.14, 212.8% above the latest close of $7.08.
Is Contineum Therapeutics a buy, hold or sell?
Of 8 analysts covering Contineum Therapeutics, 5 rate it a strong buy, 1 a buy, 2 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Contineum Therapeutics's EPS forecast?
Analysts forecast −$1.70 per share for 2026 (range −$1.85 to −$1.52); for 2027 the estimate is −$1.93.
When does Contineum Therapeutics report earnings?
Contineum Therapeutics is expected to report results for the quarter ending September 30, 2026 on October 29, 2026 after the market closes; the EPS estimate is $-0.45.
Does Contineum Therapeutics usually beat earnings estimates?
Contineum Therapeutics reported EPS at or above the analyst estimate in 5 of the last 11 quarters.